Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

Signalling through the interleukin (IL)-6 pathway induces proliferation and drug resistance of multiple myeloma cells. We therefore sought to determine whether the IL-6-neutralizing monoclonal antibody siltuximab, formerly CNTO 328, could enhance the activity of melphalan, and to examine some of the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hunsucker, Sally A., Magarotto, Valeria, Kuhn, Deborah J., Kornblau, Steven M., Wang, Michael, Weber, Donna M., Thomas, Sheeba K., Shah, Jatin J., Voorhees, Peter M., Xie, Hong, Cornfeld, Mark, Nemeth, Jeffrey A., Orlowski, Robert Z.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3402914/
https://ncbi.nlm.nih.gov/pubmed/21241278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08533.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados